Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs

Abdishakur Abdulle, Claire K. Inman, Abdelkarim Saleh, Mohamed Noshi, Divya Galani, Laila Abdelwareth, Habiba Alsafar, Abubaker Elfatih, Hefsa Al Shamsi, Raghib Ali, Huilin Li, Ravichandran Ramasamy, Ann Marie Schmidt, Mahmoud M. Benbarka, Mohamed H. Hassan

Research output: Contribution to journalArticle

Abstract

Background: The United Arab Emirates is experiencing increasing rates of type 2 diabetes (T2D) and its complications. As soluble levels of the receptor for advanced glycation end products, (sRAGE), and endogenous secretory RAGE (esRAGE), the latter an alternatively spliced form of AGER (the gene encoding RAGE), have been reported to be associated with T2D and its complications, we tested for potential relationships between these factors and T2D status in Emirati subjects. Methods: In a case-control study, we recruited Emirati subjects with T2D and controls from the Sheikh Khalifa Medical City in Abu Dhabi. Anthropomorphic characteristics, levels of plasma sRAGE and esRAGE, and routine chemistry variables were measured. Results: Two hundred and sixteen T2D subjects and 215 control subjects (mean age, 57.4 ± 12.1 vs. 50.7 ± 15.4 years; P < 0.0001, respectively) were enrolled. Univariate analyses showed that levels of sRAGE were significantly lower in the T2D vs. control subjects (1033.9 ± 545.3 vs. 1169.2 ± 664.1 pg/ml, respectively; P = 0.02). Multivariate analyses adjusting for age, sex, systolic blood pressure, pulse, body mass index, Waist/Hip circumference ratio, fasting blood glucose, HDL, LDL, insulin, triglycerides, Vitamin D and urea levels revealed that the difference in sRAGE levels between T2D and control subjects remained statistically-significant, P = 0.03, but not after including estimated glomerular filtration rate in the model, P = 0.14. There were no significant differences in levels of esRAGE. Levels of plasma insulin were significantly higher in the control vs. the T2D subjects (133.6 ± 149.9 vs. 107.6 ± 93.3 pg/L. respectively; P = 0.01, after adjustment for age and sex). Conclusion/discussion: Levels of sRAGE, but not esRAGE, were associated with T2D status in Abu Dhabi, but not after correction for eGFR. Elevated levels of plasma insulin in both control and T2D subjects suggests the presence of metabolic dysfunction, even in subjects without diabetes.

Original languageEnglish (US)
Article number100192
JournalJournal of Clinical and Translational Endocrinology
Volume16
DOIs
StatePublished - Jun 1 2019

Fingerprint

United Arab Emirates
Type 2 Diabetes Mellitus
Diabetes Complications
Insulin
Blood Pressure
Waist-Hip Ratio
Waist Circumference
Glomerular Filtration Rate
Vitamin D
Blood Glucose
Urea
Case-Control Studies
Fasting
Body Mass Index
Multivariate Analysis
Advanced Glycosylation End Product-Specific Receptor

Keywords

  • esRAGE (endogenous secretory RAGE)
  • Insulin resistance
  • Kidney function
  • Receptor for advanced glycation endproducts (RAGE)
  • Soluble RAGE (sRAGE)
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Metabolic dysfunction in Emirati subjects in Abu Dhabi : Relationship to levels of soluble RAGEs. / Abdulle, Abdishakur; Inman, Claire K.; Saleh, Abdelkarim; Noshi, Mohamed; Galani, Divya; Abdelwareth, Laila; Alsafar, Habiba; Elfatih, Abubaker; Al Shamsi, Hefsa; Ali, Raghib; Li, Huilin; Ramasamy, Ravichandran; Schmidt, Ann Marie; Benbarka, Mahmoud M.; Hassan, Mohamed H.

In: Journal of Clinical and Translational Endocrinology, Vol. 16, 100192, 01.06.2019.

Research output: Contribution to journalArticle

Abdulle, A, Inman, CK, Saleh, A, Noshi, M, Galani, D, Abdelwareth, L, Alsafar, H, Elfatih, A, Al Shamsi, H, Ali, R, Li, H, Ramasamy, R, Schmidt, AM, Benbarka, MM & Hassan, MH 2019, 'Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs', Journal of Clinical and Translational Endocrinology, vol. 16, 100192. https://doi.org/10.1016/j.jcte.2019.100192
Abdulle, Abdishakur ; Inman, Claire K. ; Saleh, Abdelkarim ; Noshi, Mohamed ; Galani, Divya ; Abdelwareth, Laila ; Alsafar, Habiba ; Elfatih, Abubaker ; Al Shamsi, Hefsa ; Ali, Raghib ; Li, Huilin ; Ramasamy, Ravichandran ; Schmidt, Ann Marie ; Benbarka, Mahmoud M. ; Hassan, Mohamed H. / Metabolic dysfunction in Emirati subjects in Abu Dhabi : Relationship to levels of soluble RAGEs. In: Journal of Clinical and Translational Endocrinology. 2019 ; Vol. 16.
@article{dcbca0b59fa747338c0b8db507017b34,
title = "Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs",
abstract = "Background: The United Arab Emirates is experiencing increasing rates of type 2 diabetes (T2D) and its complications. As soluble levels of the receptor for advanced glycation end products, (sRAGE), and endogenous secretory RAGE (esRAGE), the latter an alternatively spliced form of AGER (the gene encoding RAGE), have been reported to be associated with T2D and its complications, we tested for potential relationships between these factors and T2D status in Emirati subjects. Methods: In a case-control study, we recruited Emirati subjects with T2D and controls from the Sheikh Khalifa Medical City in Abu Dhabi. Anthropomorphic characteristics, levels of plasma sRAGE and esRAGE, and routine chemistry variables were measured. Results: Two hundred and sixteen T2D subjects and 215 control subjects (mean age, 57.4 ± 12.1 vs. 50.7 ± 15.4 years; P < 0.0001, respectively) were enrolled. Univariate analyses showed that levels of sRAGE were significantly lower in the T2D vs. control subjects (1033.9 ± 545.3 vs. 1169.2 ± 664.1 pg/ml, respectively; P = 0.02). Multivariate analyses adjusting for age, sex, systolic blood pressure, pulse, body mass index, Waist/Hip circumference ratio, fasting blood glucose, HDL, LDL, insulin, triglycerides, Vitamin D and urea levels revealed that the difference in sRAGE levels between T2D and control subjects remained statistically-significant, P = 0.03, but not after including estimated glomerular filtration rate in the model, P = 0.14. There were no significant differences in levels of esRAGE. Levels of plasma insulin were significantly higher in the control vs. the T2D subjects (133.6 ± 149.9 vs. 107.6 ± 93.3 pg/L. respectively; P = 0.01, after adjustment for age and sex). Conclusion/discussion: Levels of sRAGE, but not esRAGE, were associated with T2D status in Abu Dhabi, but not after correction for eGFR. Elevated levels of plasma insulin in both control and T2D subjects suggests the presence of metabolic dysfunction, even in subjects without diabetes.",
keywords = "esRAGE (endogenous secretory RAGE), Insulin resistance, Kidney function, Receptor for advanced glycation endproducts (RAGE), Soluble RAGE (sRAGE), Type 2 diabetes",
author = "Abdishakur Abdulle and Inman, {Claire K.} and Abdelkarim Saleh and Mohamed Noshi and Divya Galani and Laila Abdelwareth and Habiba Alsafar and Abubaker Elfatih and {Al Shamsi}, Hefsa and Raghib Ali and Huilin Li and Ravichandran Ramasamy and Schmidt, {Ann Marie} and Benbarka, {Mahmoud M.} and Hassan, {Mohamed H.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.jcte.2019.100192",
language = "English (US)",
volume = "16",
journal = "Journal of Clinical and Translational Endocrinology",
issn = "2214-6237",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Metabolic dysfunction in Emirati subjects in Abu Dhabi

T2 - Relationship to levels of soluble RAGEs

AU - Abdulle, Abdishakur

AU - Inman, Claire K.

AU - Saleh, Abdelkarim

AU - Noshi, Mohamed

AU - Galani, Divya

AU - Abdelwareth, Laila

AU - Alsafar, Habiba

AU - Elfatih, Abubaker

AU - Al Shamsi, Hefsa

AU - Ali, Raghib

AU - Li, Huilin

AU - Ramasamy, Ravichandran

AU - Schmidt, Ann Marie

AU - Benbarka, Mahmoud M.

AU - Hassan, Mohamed H.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: The United Arab Emirates is experiencing increasing rates of type 2 diabetes (T2D) and its complications. As soluble levels of the receptor for advanced glycation end products, (sRAGE), and endogenous secretory RAGE (esRAGE), the latter an alternatively spliced form of AGER (the gene encoding RAGE), have been reported to be associated with T2D and its complications, we tested for potential relationships between these factors and T2D status in Emirati subjects. Methods: In a case-control study, we recruited Emirati subjects with T2D and controls from the Sheikh Khalifa Medical City in Abu Dhabi. Anthropomorphic characteristics, levels of plasma sRAGE and esRAGE, and routine chemistry variables were measured. Results: Two hundred and sixteen T2D subjects and 215 control subjects (mean age, 57.4 ± 12.1 vs. 50.7 ± 15.4 years; P < 0.0001, respectively) were enrolled. Univariate analyses showed that levels of sRAGE were significantly lower in the T2D vs. control subjects (1033.9 ± 545.3 vs. 1169.2 ± 664.1 pg/ml, respectively; P = 0.02). Multivariate analyses adjusting for age, sex, systolic blood pressure, pulse, body mass index, Waist/Hip circumference ratio, fasting blood glucose, HDL, LDL, insulin, triglycerides, Vitamin D and urea levels revealed that the difference in sRAGE levels between T2D and control subjects remained statistically-significant, P = 0.03, but not after including estimated glomerular filtration rate in the model, P = 0.14. There were no significant differences in levels of esRAGE. Levels of plasma insulin were significantly higher in the control vs. the T2D subjects (133.6 ± 149.9 vs. 107.6 ± 93.3 pg/L. respectively; P = 0.01, after adjustment for age and sex). Conclusion/discussion: Levels of sRAGE, but not esRAGE, were associated with T2D status in Abu Dhabi, but not after correction for eGFR. Elevated levels of plasma insulin in both control and T2D subjects suggests the presence of metabolic dysfunction, even in subjects without diabetes.

AB - Background: The United Arab Emirates is experiencing increasing rates of type 2 diabetes (T2D) and its complications. As soluble levels of the receptor for advanced glycation end products, (sRAGE), and endogenous secretory RAGE (esRAGE), the latter an alternatively spliced form of AGER (the gene encoding RAGE), have been reported to be associated with T2D and its complications, we tested for potential relationships between these factors and T2D status in Emirati subjects. Methods: In a case-control study, we recruited Emirati subjects with T2D and controls from the Sheikh Khalifa Medical City in Abu Dhabi. Anthropomorphic characteristics, levels of plasma sRAGE and esRAGE, and routine chemistry variables were measured. Results: Two hundred and sixteen T2D subjects and 215 control subjects (mean age, 57.4 ± 12.1 vs. 50.7 ± 15.4 years; P < 0.0001, respectively) were enrolled. Univariate analyses showed that levels of sRAGE were significantly lower in the T2D vs. control subjects (1033.9 ± 545.3 vs. 1169.2 ± 664.1 pg/ml, respectively; P = 0.02). Multivariate analyses adjusting for age, sex, systolic blood pressure, pulse, body mass index, Waist/Hip circumference ratio, fasting blood glucose, HDL, LDL, insulin, triglycerides, Vitamin D and urea levels revealed that the difference in sRAGE levels between T2D and control subjects remained statistically-significant, P = 0.03, but not after including estimated glomerular filtration rate in the model, P = 0.14. There were no significant differences in levels of esRAGE. Levels of plasma insulin were significantly higher in the control vs. the T2D subjects (133.6 ± 149.9 vs. 107.6 ± 93.3 pg/L. respectively; P = 0.01, after adjustment for age and sex). Conclusion/discussion: Levels of sRAGE, but not esRAGE, were associated with T2D status in Abu Dhabi, but not after correction for eGFR. Elevated levels of plasma insulin in both control and T2D subjects suggests the presence of metabolic dysfunction, even in subjects without diabetes.

KW - esRAGE (endogenous secretory RAGE)

KW - Insulin resistance

KW - Kidney function

KW - Receptor for advanced glycation endproducts (RAGE)

KW - Soluble RAGE (sRAGE)

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85064968061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064968061&partnerID=8YFLogxK

U2 - 10.1016/j.jcte.2019.100192

DO - 10.1016/j.jcte.2019.100192

M3 - Article

AN - SCOPUS:85064968061

VL - 16

JO - Journal of Clinical and Translational Endocrinology

JF - Journal of Clinical and Translational Endocrinology

SN - 2214-6237

M1 - 100192

ER -